Autophagosome–lysosome fusion machinery (None standard)

This target is not a single molecule or receptor but a conglomerate of proteins and complexes that mediate the terminal step of autophagy: fusion of the autophagosome with the lysosome. Key molecular components include two major SNARE complexes (Stx17-SNAP29-VAMP7/8 and YKT6-SNAP29-Stx7), the HOPS tethering complex, Rab GTPases (notably Rab7 and Arl8b), and accessory factors such as EPG5 and PLEKHM1[1][3][4]. This machinery ensures cargo degradation, maintains cellular homeostasis, and is tightly regulated. Dysregulation of fusion is implicated in human diseases, and pharmacological manipulation of autophagy influences these processes. However, currently there are no drugs that selectively or directly target the fusion machinery itself, and thus it represents a molecular pathway rather than a classic receptor, transporter, or enzyme target[1][3][4].

Other names

Autophagosome–lysosome fusion complexautophagy fusion machineryautolysosome formation machinery

Drugs affecting this machinery typically modulate autophagy induction, lysosomal function, or block fusion (e.g., chloroquine blocks autophagosome–lysosome fusion by raising lysosomal pH). Indirect mechanisms include mTOR inhibition (rapamycin) and modulation of AMPK.